ArQule-Pfizer deal breaks mold

Article Abstract:

ArQule, a biotechnology company in Medford Mass., signed a technology transfer deal with Pfizer. The deal is worth $117 million and will include the production of exclusive microarray libraries to Pfizer and make it available nonexclusively to Pfizer for another 4.5 years.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Sequenom steps toward drug development

Article Abstract:

Cambridge, UK-based clinical genomics company Gemini Genomics and San Diego, CA-based genetic analysis firm Sequenom have decided to merge their businesses in a stock-for-stock deal worth $238 million.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code:

Chiral drugs viable, despite failure

Article Abstract:

Eli Lilly decided not to re-engineer Sepracor's Prozac, an action that is usually done to maintain a drug patent, which resulted in some financial uncertainty in Sepracor.

User Contributions:

Comment about this article or add new information about this topic:

Comment:  (50-4000 characters)

Name:

E-mail:

Security Code: